title: Lipids in liver transplant recipients.
abstract: Hyperlipidemia is very common after liver transplantation and can be observed in up to 71% of patients. The etiology of lipid disorders in these patients is multifactorial, with different lipid profiles observed depending on the immunosuppressive agents administered and the presence of additional risk factors, such as obesity, diabetes mellitus and nutrition. Due to recent improvements in survival of liver transplant recipients, the prevention of cardiovascular events has become more important, especially as approximately 64% of liver transplant recipients present with an increased risk of cardiovascular events. Management of dyslipidemia and of other modifiable cardiovascular risk factors, such as hypertension, diabetes and smoking, has therefore become essential in these patients. Treatment of hyperlipidemia after liver transplantation consists of life style modification, modifying the dose or type of immunosuppressive agents and use of lipid lowering agents. At the start of administration of lipid lowering medications, it is important to monitor drug-drug interactions, especially between lipid lowering agents and immunosuppressive drugs. Furthermore, as combinations of various lipid lowering drugs can lead to severe side effects, such as myopathies and rhabdomyolysis, these combinations should therefore be avoided. To our knowledge, there are no current guidelines targeting the management of lipid metabolism disorders in liver transplant recipients. This paper therefore recommends an approach of managing lipid abnormalities occurring after liver transplantation.
authors.affiliation: Anna Hüsing, Iyad Kabar, Hartmut H Schmidt, Department of Transplant Medicine, University Hospital Münster, 48149 Münster, Germany.
authors.forename: Anna
authors.initials: A
authors.lastname: Hüsing
authors.affiliation: Anna Hüsing, Iyad Kabar, Hartmut H Schmidt, Department of Transplant Medicine, University Hospital Münster, 48149 Münster, Germany.
authors.forename: Iyad
authors.initials: I
authors.lastname: Kabar
authors.affiliation: Anna Hüsing, Iyad Kabar, Hartmut H Schmidt, Department of Transplant Medicine, University Hospital Münster, 48149 Münster, Germany.
authors.forename: Hartmut H
authors.initials: HH
authors.lastname: Schmidt
mesh_terms: D015415:Biomarkers / Q000097:blood; D004347:Drug Interactions; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D000960:Hypolipidemic Agents / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008055:Lipids / Q000097:blood*; D016031:Liver Transplantation / Q000009:adverse effects*; D012307:Risk Factors; D066027:Transplant Recipients; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; D008055:Lipids
keywords: Dyslipidemia; Immunosuppression; Lipid management; Liver transplantation; Treatment; mTOR-inhibition